DOI: Origa R, Satta S, Matta G, Galanello R
Summary: Rybelsus is the first oral GLP-1 receptor agonist (semaglutide) licensed in the UK for treating type 2 diabetes in adults, offering a convenient tablet alternative to injectable GLP-1 therapies
This suggests that choosing resistant starch sourceslike oats, beans and cooked-and-cooled potatoesmay help support appetite control and metabolic health
Deri hcrelerinde olduu gibi, i organlarn da daha hzl iyilemesini salar
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone